SAB Biotherapeutics SABS
NASDAQ SABS
$2.91 +0.03 (+1.04%)
As of: Oct 21, 2026 · 11:36 AM EDT

SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

Updated

SAB Biotherapeutics (SABS) reported Construction in Progress of $329,617 for Q1 2023, up 6.9% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023) Analysis & Trends

At the end of FY2022, SAB Biotherapeutics posted Construction in Progress of $308,317, down 93.3% from FY2021.

  • By year, Construction in Progress came in at $4.61 million in FY2021.
  • The Q1 2023 figure ranks as the highest quarterly Construction in Progress since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn -
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn -
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn -
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn -
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn -
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn -
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn -
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn -
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn -
10 SAB Biotherapeutics 232.08 Mn -185.42 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 329,617.00
Dec 31, 2022 308,317.00
Dec 31, 2021 4.61 Mn
API Access

SAB Biotherapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=SABS&period=max&api_key=YOUR_API_KEY